coronavirus oral medication on the national market
Malnupiravir, a new anti-coronavirus drug in the UK, has entered the Bangladesh market.
out of 10 authorized companies, beximco Pharmaceuticals has already started marketing the drug, said Major General Md. said mahbubur rahman.
he said at a press conference on Tuesday that skf and square pharmaceuticals had also received approval for the manufacture and marketing of drugs on Tuesday. Insepta, health care, decami, popular, beacon, renata and common medicine await approval.
"This is the first time that an antiretroviral drug has been introduced into our country. Yesterday we provided emergency use and marketing authorization for the masses and today on skf. We are also applying to other institutions for emergency use.
he said “as a developing country”, drug companies in Bangladesh are able to deliver the drug as soon as possible as there is an opportunity to “discontinue” certain drugs.
you should take four to eight pills every two hours daily. The course of this drug will last 5 days. each 200 mg capsule will cost rs 50. the director general of the drug administration department said the drug should be taken as prescribed by a doctor.
said the coronavirus drug has been tested in about 170 locations around the world. results were positive and approved in uk.
"We have also tested it in our country. We have approved the emergency use of this drug based on approval in the UK and positive results in our trials."
however, Mahbubur rahman warned that the drug could not be used without a doctor's advice and that anyone under the age of eighteen would use the drug for those suffering from mild and moderate covid levels.
"The effectiveness of this drug is good. Studies have shown that hospitalization and mortality can be reduced by 50 percent. There were also no reports of serious side effects."
bekmco Pharmaceuticals limited chief executive rabbur reza told bdnews.com on Tuesday that each 200 mg capsule costs R270. 2,800.
two u.s. companies, mark sharp & dom (msd) and rizebak biotherapeutic, have developed a combined oral drug, lagevrio (malnupiravir).
previously, experimental applications showed that the drug they had administered was able to reduce the rate of hospitalization or serious illness by 50 percent in patients with covid at high risk of malnupiravi.
The first oral medication for coronavirus symptoms last Thursday was approved by the UK Drug Administration and Healthcare Association (mhra).
0 Comments